Solid Biosciences (SLDB) Falls Despite FDA Rare Tag for DMD Drug
https://www.zacks.com/stock/news/2249187/solid-biosciences-sldb-falls-despite-fda-rare-tag-for-dmd-drug?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2249187
Apr 02, 2024 - Solid Biosciences' (SLDB) novel gene-therapy candidate, SGT-003, gets FDA's Rare Pediatric Disease Designation for the treatment of Duchenne muscular dystrophy.
0
Rare Stock Picks In March 2024 - From 24 Discerning Analysts
https://seekingalpha.com/article/4681746-rare-stock-picks-in-march-2024-from-24-discerning-analysts?source=feed
Apr 03, 2024 - In our monthly Rare Stock Picks series, we're highlighting March 2024 investment picks. Click here for the list of March 2024 Buy recommendations.
0
REMX: This Rare Earth And Metals ETF Appears Poised For A Breakout
https://seekingalpha.com/article/4683379-remx-rare-earth-and-metals-etf-appears-poised-for-breakout?source=feed_tag_etf_portfolio_strategy
Apr 11, 2024 - VanEck Rare Earth/Strategic Metals ETF is a diversified investment option with potential for rebound amidst rising demand and prices. Read more on REMX here.
0
As more rare disease therapies launch, their prices are rising
https://seekingalpha.com/news/4089415-more-rare-disease-therapies-launch-their-prices-rising?source=feed_sector_healthcare
Apr 16, 2024 - Rare disease therapies are extremely expensive, with some costing millions of dollars. They are getting even more pricey. Read more here.
0
Novartis wins pediatric indication for Lutathera for rare cancer
https://seekingalpha.com/news/4092720-novartis-wins-pediatric-indication-lutathera-rare-cancer?source=feed_sector_healthcare
Apr 23, 2024 - Novartis' Lutathera has received FDA approval for children aged 12 and above with certain types of neuroendocrine tumors, a rare form of cancer. Read more here.
0
There's a Rare $25 Discount on the Nintendo Switch OLED Right Now
https://www.wired.com/story/nintendo-switch-oled-deal-april-2024/
Apr 25, 2024 - Nintendo's top-of-the-line handheld gaming console hardly ever goes on sale, making this small discount super appealing.
0
FDA approves Pfizer’s first gene therapy for rare inherited bleeding disorder
https://www.cnbc.com/2024/04/26/fda-approves-pfizer-gene-therapy-beqvez-for-treatment-of-hemophilia-b.html
Apr 26, 2024 - The agency greenlighted the drug, which will be marketed as Beqvez, for adults with moderate to severe hemophilia B.
0
Harmony Biosciences acquires Epygenix gaining rare epilepsy pipeline
https://seekingalpha.com/news/4096206-harmony-biosciences-acquires-epygenix-gaining-rare-epilepsy-pipeline?source=feed_sector_healthcare
Apr 30, 2024 - Harmony Biosciences acquires Epygenix Therapeutics for $35M upfront, focusing on developing treatments for rare epilepsy conditions. Read more here.
0
Ultragenyx (RARE) Reports Q1 Earnings: What Key Metrics Have to Say
https://www.zacks.com/stock/news/2267565/ultragenyx-rare-reports-q1-earnings-what-key-metrics-have-to-say?cid=CS-ZC-FT-fundamental_analysis|nfm-2267565
May 02, 2024 - While the top- and bottom-line numbers for Ultragenyx (RARE) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
0
A rare hostile takeover bid in Europe's banking sector has shocked markets
https://www.cnbc.com/2024/05/09/spains-bbva-launches-rare-hostile-takeover-bid-for-rival-sabadell.html
May 09, 2024 - Spanish bank BBVA caught markets by surprise after it announced a rare hostile takeover bid for domestic rival Banco Sabadell.
0